Company: TVRD
Filing Date: 2025-05-30
Form Type: S-1
Source: 0001104659-25-054853
Chunk: 262

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-05-30
Form: S-1
Chunk 262
---
 in 2024. |

| (6) | Ms. Smith was appointed to our board of directors upon the closing of the Merger. Dr. Shiff remained on our board of directors as a designee of Cara upon the closing of the Merger. Neither Ms. Smith nor Dr. Shiff received compensation from Legacy Tvardi for 2024. Dr. Shiff received compensation from Cara for her service as a member of the Cara board of directors in 2024 see the table below for Cara’s non-employee director compensation for 2024. |

150

The following table shows certain information with respect to the compensation of all of Cara’s non-employee directors for the fiscal year ended December 31, 2024:

| ​                      
 ​                      
 ​                      
 ​                      
 Director               | ​ 
 ​ 
 ​ 
 ​ |           ​ 
 Fees earned 
  or paid in 
     cash(1) 
         ($) | ​ 
 ​ 
 ​ 
 ​ |            ​ 
            ​ 
        Stock 
 awards(2)(3) 
          ($) | ​ 
 ​ 
 ​ 
 ​ |            ​ 
            ​ 
       Option 
 awards(2)(3) 
          ($) | ​ 
 ​ 
 ​ 
 ​ | ​     
 ​     
 ​     
 Total 
 ($)   |       ​ 
       ​ 
       ​ |
|:-----------------------|:--|------------:|:--|-------------:|:--|-------------:|:--|:------|--------:|
| Jeffrey L. Ives, Ph.D. | ​ |      72,500 | ​ |      100,000 | ​ |      100,000 | ​ | $     | 272,500 |
| Martin Vogelbaum       | ​ |     120,000 | ​ |      200,000 | ​ |      200,000 | ​ | $     | 520,000 |
| Lisa von Moltke        | ​ |      55,000 | ​ |      100,000 | ​ |      100,000 | ​ | $     | 255,000 |
| Susan Shiff, Ph.D.     |   |      62,500 |   |      100,000 |   |      100,000 | ​ | $     | 262,500 |
| Helen M. Boudreau      |   |      70,000 |   |      100,000 |   |      100,000 | ​ |